Status:
TERMINATED
Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The purpose of this study is to identify which patients, receiving Faslodex within the approved label, benefit most from Faslodex treatment.
Eligibility Criteria
Inclusion
- Postmenopausal
- Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status
- Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment
Exclusion
- Life threatening metastases
Key Trial Info
Start Date :
June 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00241462
Start Date
June 1 2005
End Date
December 1 2009
Last Update
April 22 2009
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Alkmaar, Netherlands
2
Research Site
Almelo, Netherlands
3
Research Site
Almere Stad, Netherlands
4
Research Site
Amsterdam, Netherlands